丹参注射液与黄芪注射液联合应用治疗冠心病心绞痛40例临床护理被引量：10

Clinical nursing care in the treatment of 40 patients with angina pectoris due to coronary heart disease by application of Salvia and Astragalus injection

下载PDF

导出

摘要目的:探讨丹参注射液与黄芪注射液联合应用治疗冠心病心绞痛的护理方法。方法:将80例冠心病心绞痛患者随机分为治疗组和对照组各40例,治疗组静脉滴注丹参注射液与黄芪注射液,对照组仅静脉滴注丹参注射液,均连续应用两个疗程,每个疗程14d,比较两组疗效。结果:治疗组心绞痛改善情况、中医证候有效率、心电图改善情况、血液流变学改变情况优于对照组,两组比较有显著性差异(P<0.05,P<0.01)。结论:丹参注射液与黄芪注射液联合应用能减轻冠心病患者心绞痛症状,改善心电图及血液流变学指标,有效缓解中医证侯,配合精心的护理,疗效优于单用丹参注射液。 Objective： To study the methods of nursing care in the treatment of angina pectoris due to coronary heart disease by application of Salvia and Astragalus injection. Methods： Eighty patients with angina pectoris were randomly divided into treatment group （ n --40） and control group （ n =40）. Salvia and Astragalus injection was intravenously given to the patients in treatment group, and Salvia injection was only given in control group. 14 days was taken as a course of treatment and 2 courses were given in both groups, and then the curative effect was compared between the two groups. Results： The improvement of angina pectoris, change of ECG and hemorheology were better and more significant in treatment group than that in control group （ P 〈 0. 05, P 〈 0. 01 ）. Conclusion： The application of Salvia and Astragalus injection can relieve symptoms of angina pectofis and effectively improve syndromes by TCM diagnosis. The curative effect is much better by using Salvia and Astragalus injection than using single Salvia injection, combining with care nursing care in the treatment of angina pectoris due to coronary heart disease.

作者王玉兰王军李环

机构地区山东中医药大学附属医院山东省警官总医院

出处《齐鲁护理杂志》 2008年第8期3-4,共2页 Journal of Qilu Nursing

关键词丹参注射液黄芪注射液冠心病心绞痛护理 Salvia injection Astragalus injection Coronary heart disease Angina pectoris Nursing

分类号 R473.5 [医药卫生—护理学]

引文网络
相关文献

参考文献4

1张嘉莹,朱中玉,李牧蔚,陈岩,王现青.青年急性心肌梗死患者脂蛋白(a)水平的变化及其意义[J].临床心血管病杂志,2002,18(10):500-502. 被引量：248
2中国中西医结合学会心血管学会.冠心病中医辨证标准[J].中西医结合杂志,1991,11(5):257-257.
3陈可冀廖家桢肖镇祥.心脑血管病研究[M].上海：上海科技出版社,1988.311-313.
4.中药新药临床研究指导原则[S].[S].中华人民共和国卫生部,1993.57.

二级参考文献7

1Luc G, Bard J M, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis, 2001,163(2):377-384.
2Seman L G, Deluca C, Jenner J L,et al. Lipoprotein (a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem, 1999,45(7):1039-1046.
3Lundstam U, Herlitz J, Karlsson T, et al. Serum lipids, lipoprtein (a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med, 2002,251(2):111-118.
4Marcovina S M, Hegele R A, Koschinsky M L. Lipoprotein (a) and coronary heart disease risk. Curr Cardiol Rep,1999,1(2):105-111.
5Angles C E. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process. Braz J Med Biol Res,1997,30(11):1271-1280.
6Maeda S, Abe A, Seishima M, et al. Transient change of serum lipoprotein (a) as an acute phase protein. Atherosclerosis, 1989,78(1):145-150.
7Greory Y H, Gordon D L. Fibrin D-dimer: A useful marker of thrombogenesis? Clini Sci,1995(89):205-214.